Company Overview - Sensei Biotherapeutics, Inc. is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients [3] - The company utilizes its TMAb™ platform to create conditionally active therapeutics that target immunosuppressive signals in the tumor microenvironment [3] - The lead product candidate is solnerstotug, an antibody designed to block the VISTA checkpoint selectively in low pH tumor environments [3] Upcoming Events - John Celebi, President and CEO of Sensei Biotherapeutics, will participate in 1x1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 [1] - An on-demand corporate presentation will be available on September 5, 2025, at 7:00 a.m. ET, with a replay accessible for approximately 90 days [2]